InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

- Current share price for MSB : $1.705

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$2,219 Trading Halt 3 May 2010 9:37AM $1.935 $1.705 fallen by 11.89%
$2,219 Appendix 4C and Clinical Trial Update 30 Apr 2010 2:11PM $1.990 $1.705 fallen by 14.32%
$2,219 Market Exclusivity Strengthened by New USA Healthcare Act 6 Apr 2010 10:34AM $2.060 $1.705 fallen by 17.23%
$2,219 Key Bone Repair Patent Granted in the United States 3 Mar 2010 9:11AM $1.940 $1.705 fallen by 12.11%
$2,219 Half Yearly Report and Accounts 25 Feb 2010 10:19AM $1.950 $1.705 fallen by 12.56%
$2,219 Appendix 4C - quarterly 29 Jan 2010 4:54PM $1.830 $1.705 fallen by 6.83%
$2,219 Response to an ASX Price Query 11 Jan 2010 8:57AM $1.960 $1.705 fallen by 13.01%
$2,219 Mesoblast - National Electronic Media Coverage 21 Dec 2009 10:38AM $1.350 $1.705 risen by 26.30%
$2,219 Cells Regenerate Pancreas and Reduce Diabetic Glucose Levels 18 Dec 2009 8:23AM $1.365 $1.705 risen by 24.91%
$2,219 Sustained 6 Month Improvement in Heart Muscle Function 18 Nov 2009 10:16AM $1.420 $1.705 risen by 20.07%
$2,219 Successful Bone Marrow Regeneration in Cancer Patients 6 Nov 2009 9:00AM $1.200 $1.705 risen by 42.08%
$2,219 Appendix 4C - quarterly 12 Oct 2009 10:41AM $1.045 $1.705 risen by 63.16%
$2,219 Enrolment Complete for 2nd Group of Heart Failure Patients 22 Sep 2009 9:17AM $1.060 $1.705 risen by 60.85%
$2,219 Successful Repair/Regeneration Damaged Intervertebral Discs 10 Sep 2009 11:58AM $1.095 $1.705 risen by 55.71%
$2,219 Preliminary Final Report 26 Aug 2009 11:59AM n/a $1.705 n/a
$2,219 USA Associate Company Closes $10M Equity-Based Financing 25 Aug 2009 10:35AM $1.060 $1.705 risen by 60.85%
$2,219 Associate Company Angioblast Systems Raises New Capital 19 Aug 2009 10:35AM $1.160 $1.705 risen by 46.98%
$2,219 Trading Halt 17 Aug 2009 1:26PM $1.190 $1.705 risen by 43.28%
$2,219 FDA Clears Trial in Minimally Invasive Lumbar Spinal Fusion 17 Aug 2009 10:07AM $1.190 $1.705 risen by 43.28%
$2,219 USA Trial to use Patented Cells with Heart Assist Devices 5 Aug 2009 8:54AM $1.185 $1.705 risen by 43.88%
$2,219 Appendix 4C - quarterly 30 Jul 2009 9:17AM $1.140 $1.705 risen by 49.56%
$2,219 MSB to Apply for Regulatory Approval of Bone Repair Products 23 Jul 2009 9:30AM $1.000 $1.705 risen by 70.50%
$2,219 Patients in Bone Marrow Trial Show Earlier Engraftment 24 Jun 2009 10:20AM $0.770 $1.705 risen by 121.43%
$2,219 Results Show Significant Heart Function Improvement 14 May 2009 9:09AM $0.770 $1.705 risen by 121.43%
$2,219 Appendix 4C - quarterly 1 May 2009 9:30AM $0.780 $1.705 risen by 118.59%

1101 - 1125 of 1213 results

Page 45 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.